RecruitingNot ApplicableNCT05165901

Clinical Effect of LG Medipain for Managing Chronic Pain Disorders

Clinical Effect of LG Medipain for Managing Chronic Pain Disorders: A Prospective Observational Study

Sponsor

Jeeyoun Moon

Enrollment

90 participants

Start Date

Jan 3, 2022

Study Type

INTERVENTIONAL

Conditions

Pain Chronic Pain Neuropathic Pain Refractory Pain

Summary

Scrambler Therapy is a type of non-invasive neuromodulation. According to the researches that studied the effects of the existing Scrambler therapy, 10 times of Scrambler Therapy showed a significant pain relief lasting for more than 1-3 months in various pain disorders such as post-herpetic neuralgia, cancer-related neuropathic pain, and mixed pain. No treatment-related side effects have been reported in Scrambler therapy conducted in previous studies. The most inconvenient thing about Scrambler Therapy is that it has to be treated more than 10 times during specific period, so frequent visits to the hospital for treatment linked to the higher burden for the patient's cost and even those are not fully covered by the government's insurance. To reduce this discomfort and expand the range of treatment in the era of Corona of untact treatment, LG Electronics devised a home self-scrambler treatment device for pain patients. The LG Medipain device has the same treatment function as the existing hospital Scrambler treatment device, but there has been no study on its efficacy and safety. Therefore, the investigators want to conduct this research and find out about the safety and equal efficiency of the LG Medipain Therapy. In this study, it is expected that pain relief and improvement of quality of life can be obtained for patients with various types of chronic pain through self-application of LG Medipain device.

Eligibility

Min Age: 19 Years

Inclusion Criteria6

Chronic pain disease (pain over 3 months) as an adult 19 years of age or older
Patients with 11-pointed NRS pain score ≥ 4 for the corresponding pain on the day of admission
Patients taking oral pain treatment drugs in the same type and dose up to 1 month before participating in the study, and taking the same medication until 1 month after participating in the study (at the time of obtaining the primary endpoint)
Those who voluntarily and in writing consent to participate in the study
A person who has agreed in writing to return the Scrambler Therapy device
By the classification of pain disorder, patients include with nociceptive pain such as joint pain, myofascial pain syndrome and with neuropathic pain such as postherpetic neuralgia, peripheral nerve injury and nerve entrapment syndrome and with mixed pain.

Exclusion Criteria10

Refusal of the patient
In case pain relief effect was not obtained in the past Scrambler Therapy
Patients currently undergoing Scrambler therapy for pain control at outpatient clinics at the Pain Center
Patients who had previously taken Scrambler Therapy 6 months before participating in the study
In case of systemic infection or local infection in the area around the treatment (the patch attachment site)
Patients who has cognitive decline that cannot understand the contents of the Numeric Pain Rating (NRS), questionnaire, and scrambler self application method
If it is difficult to self-administer 10 scrambler treatments for 2 weeks during the treatment period
Women during pregnancy
In case of implantation of a pacemaker, brain stimulator, etc.
Those who are not suitable for this clinical trial under the judgment of other investigators